Design Therapeutics, Inc.
Design Therapeutics, Inc. (Nasdaq: DSGN) is a clinical-stage biopharmaceutical company pioneering the development of GeneTAC® molecules, a novel class of small-molecule gene targeted chimera therapeutic candidates designed to address inherited nucleotide repeat expansion diseases. The company's website is… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Design Therapeutics, Inc. does
In the company’s own words
Design Therapeutics, Inc. (Nasdaq: DSGN) is a clinical-stage biopharmaceutical company pioneering the development of GeneTAC® molecules, a novel class of small-molecule gene targeted chimera therapeutic candidates designed to address inherited nucleotide repeat expansion diseases. The company's website is www.designtherapeutics.com.
Design Therapeutics focuses on developing disease-modifying treatments for monogenic genetic disorders caused by abnormally expanded DNA sequences. The company's GeneTAC® platform represents a heterobifunctional small-molecule approach that combines DNA-targeting moieties with ligand moieties to selectively modulate gene expression at the site of disease-causing mutations. Unlike other genomic medicine modalities, GeneTAC® molecules are designed to preserve normal physiological regulation while avoiding immunogenicity concerns associated with complex biologics.
The company's pipeline includes four primary programs in clinical or late preclinical development. DT-216P2 is in Phase 1/2 clinical trials for Friedreich ataxia, a progressive neurodegenerative disease affecting approximately 5,000 individuals in the United States. DT-168 is an eye drop formulation in Phase 2 development for Fuchs endothelial corneal dystrophy, an eye disease affecting millions of people. DT-818, announced in the fourth quarter of 2025, represents the company's development candidate for myotonic dystrophy type-1 and entered clinical development in early 2026. The company is also conducting preclinical studies on GeneTAC® candidates for Huntington's disease and advancing research programs targeting additional nucleotide repeat expansion diseases.
Design Therapeutics was founded to leverage proprietary expertise in transcriptional regulation and DNA-targeting chemistry to create a potentially broad platform applicable across more than forty debilitating degenerative diseases caused by nucleotide repeat expansions. The company believes its GeneTAC® approach offers advantages over existing genomic medicine technologies, including improved tolerability, reduced immunogenicity, reversibility, scalable manufacturing, and the ability to achieve therapeutic biodistribution without specialized delivery technologies. The company intends to independently commercialize approved products in indications and geographies where it can maximize value while selectively pursuing strategic collaborations in other areas.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- CARLSBAD, CA
- Fiscal year end
- December
- CIK
- 1807120
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Design Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Design Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Design Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Design Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Design Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”